Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 75 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is K  [Clear All Filters]
2021
Hassan-Zahraee M, Ye Z, Xi L, Baniecki MLynn, Li X, Hyde CL, Zhang J, Raha N, Karlsson F, Quan J et al..  2021.  Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.. Inflamm Bowel Dis.
Hassan-Zahraee M, Ye Z, Xi L, Baniecki MLynn, Li X, Hyde CL, Zhang J, Raha N, Karlsson F, Quan J et al..  2021.  Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.. Inflamm Bowel Dis.
Shen B, Kochhar GS, Kariv R, Liu X, Navaneethan U, Rubin DT, Cross RK, Sugita A, D'Hoore A, Schairer J et al..  2021.  Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.. Lancet Gastroenterol Hepatol. 6(10):826-849.
Shen B, Kochhar GS, Kariv R, Liu X, Navaneethan U, Rubin DT, Cross RK, Sugita A, D'Hoore A, Schairer J et al..  2021.  Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.. Lancet Gastroenterol Hepatol. 6(10):826-849.
Shen B, Kochhar GS, Kariv R, Liu X, Navaneethan U, Rubin DT, Cross RK, Sugita A, D'Hoore A, Schairer J et al..  2021.  Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.. Lancet Gastroenterol Hepatol. 6(10):826-849.
Shen B, Kochhar GS, Kariv R, Liu X, Navaneethan U, Rubin DT, Cross RK, Sugita A, D'Hoore A, Schairer J et al..  2021.  Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.. Lancet Gastroenterol Hepatol. 6(10):826-849.
Shen B, Kochhar GS, Kariv R, Liu X, Navaneethan U, Rubin DT, Cross RK, Sugita A, D'Hoore A, Schairer J et al..  2021.  Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.. Lancet Gastroenterol Hepatol. 6(10):826-849.
Shen B, Kochhar GS, Kariv R, Liu X, Navaneethan U, Rubin DT, Cross RK, Sugita A, D'Hoore A, Schairer J et al..  2021.  Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.. Lancet Gastroenterol Hepatol. 6(10):826-849.
Kayal M, Ungaro RC, Riggs A, Kamal K, Agrawal M, Cohen-Mekelburg S, Axelrad J, Faye A, Scherl E, Lawlor G et al..  2021.  Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant Disability.. Clin Gastroenterol Hepatol.
Kayal M, Ungaro RC, Riggs A, Kamal K, Agrawal M, Cohen-Mekelburg S, Axelrad J, Faye A, Scherl E, Lawlor G et al..  2021.  Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant Disability.. Clin Gastroenterol Hepatol.
Battat R, Lukin D, Scherl EJ, Pola S, Kumar A, Okada L, Yang L, Jain A, Siegel CA.  2021.  Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 27(9):1443-1451.
Ma C, Sedano R, Almradi A, Casteele NVande, Parker CE, Guizzetti L, Schaeffer DF, Riddell RH, Pai RK, Battat R et al..  2021.  An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.. Gastroenterology. 160(7):2291-2302.
Lewis JD, Sandler RS, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF et al..  2021.  A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.. Gastroenterology. 161(3):837-852.e9.
Gu W, Wang H, Huang X, Kraiczy J, Singh PNP, Ng C, Dagdeviren S, Houghton S, Pellon-Cardenas O, Lan Y et al..  2021.  SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.. Cell Stem Cell.
Zegarra-Ruiz DF, Kim DV, Norwood K, Kim M, Wu W-JH, Saldana-Morales FB, Hill AA, Majumdar S, Orozco S, Bell R et al..  2021.  Thymic development of gut-microbiota-specific T cells.. Nature. 594(7863):413-417.
Zegarra-Ruiz DF, Kim DV, Norwood K, Kim M, Wu W-JH, Saldana-Morales FB, Hill AA, Majumdar S, Orozco S, Bell R et al..  2021.  Thymic development of gut-microbiota-specific T cells.. Nature. 594(7863):413-417.
Malik F, Scherl E, Weber U, Carrino JA, Epsten M, Wichuk S, Pedersen SJ, Paschke J, Schwartzman S, Kroeber G et al..  2021.  Utility of magnetic resonance imaging in Crohn's associated sacroiliitis: A cross-sectional study.. Int J Rheum Dis.
2020
Lukin DJ, Kumar A, Hajifathalian K, Sharaiha RZ, Scherl EJ, Longman RS.  2020.  Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.. Gastroenterology. 159(4):1541-1544.e2.
Kumar A, Teslova T, Taub E, Miller JD, Lukin DJ.  2020.  Comorbid Diabetes in Inflammatory Bowel Disease Predicts Adverse Disease-Related Outcomes and Infectious Complications.. Dig Dis Sci.
Kumar A, Lukin D, Battat R, Schwartzman M, Mandl LA, Scherl E, Longman RS.  2020.  Defining the phenotype, pathogenesis and treatment of Crohn's disease associated spondyloarthritis.. J Gastroenterol. 55(7):667-678.
Dulai PS, Singh S, Casteele NVande, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A et al..  2020.  Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.. Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Dulai PS, Singh S, Casteele NVande, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A et al..  2020.  Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.. Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Dulai PS, Singh S, Casteele NVande, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A et al..  2020.  Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.. Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Kumar A, Lukin DJ.  2020.  Incident heart failure is a predictor of adverse outcomes in inflammatory bowel disease.. Eur J Gastroenterol Hepatol. 32(2):205-215.
Kumar A, Magro C, Lukin DJ.  2020.  Scattered Skin Eruptions in a Patient With Inflammatory Bowel Disease.. Gastroenterology.